Merck Drug Shows Gains Against Liver Disease

Merck's investigational efinopegdutide improved MASH resolution and liver fibrosis in a Phase 2b trial.

Updated on Nov. 9, 2026 in Diabetes

Clear glass vials of pale amber liquid and a translucent petri dish on a brushed steel laboratory bench in soft window light.
Merck's investigational once-weekly drug efinopegdutide resolved liver inflammation in 56% to 63% of MASH patients after 52 weeks, versus 13% on placebo. AI Illustration. Upload story photo >

Merck reported positive results from a mid-stage trial of efinopegdutide, an investigational once-weekly treatment for metabolic dysfunction-associated steatohepatitis (MASH). Between 56% and 63% of participants receiving the drug achieved MASH resolution without worsening of liver fibrosis after 52 weeks, compared with 13% on placebo.

Why it matters

MASH is a chronic inflammatory liver disease that can progress to cirrhosis and liver failure, underscoring the need for additional treatment options. The results suggest efinopegdutide could offer meaningful improvements in both liver inflammation and fibrosis.

The Phase 2b study met its primary efficacy endpoint, with 56% to 63% of participants on efinopegdutide reaching MASH resolution without fibrosis worsening versus 13% on placebo at 52 weeks. The safety profile was generally consistent with semaglutide, and the study did not yet report long-term clinical outcomes.

The players

Merck

Merck is a multinational pharmaceutical company headquartered in Rahway, New Jersey, that develops treatments across oncology, vaccines, and metabolic diseases.

The details

Efinopegdutide targets both glucagon-like peptide-1 (GLP-1) and glucagon receptors and is administered once weekly. The treatment also improved liver fibrosis without worsening steatohepatitis, a key secondary endpoint.

Timeline

  1. Participants were measured for primary endpoints after 52 weeks of treatment.

  2. Merck announced the trial results on Monday, November 9, 2026.

Health Landscape

Efinopegdutide builds on the GLP-1 drug class led by semaglutide, adding glucagon receptor activity that may address liver-specific disease mechanisms. The trial's safety profile was described as generally consistent with semaglutide, placing it within a familiar treatment category for metabolic liver disease.

For patients with MASH, the results point toward a possible future treatment that targets liver inflammation and fibrosis rather than only metabolic markers. Any eventual access will depend on later-stage trial results and regulatory review, which are not yet complete.

The takeaway

Efinopegdutide's trial results offer early evidence of liver benefit from a dual GLP-1 and glucagon approach, though long-term outcomes remain to be established. Readers managing metabolic liver disease should watch for further trial data and regulatory updates.

Further reading

For more on the metabolic drugs in this class, explore our Diabetes coverage.